Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
Fertility and Sterility
|
June 9, 2006
Fertility after discontinuation of treatment with an oral contraceptive containing 30 microg of ethinyl estradiol and 2 mg of dienogest
Inka Wiegratz, Katrin Mittmann, Horst Dietrich, et al.
Reproductive Biology and Endocrinology : RB&E
|
May 28, 2020
Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study
Peter Sydow, Norbert Gmeinwieser, Katrin Pribbernow, et al.
International Journal of Women'S Health
|
January 23, 2015
Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
Inka Wiegratz, Jörg Elliesen, Anna Maria Paoletti, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|
February 18, 2020
Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 μg) and levonorgestrel (150 μg) in a randomized controlled trial
Peyman Hadji, Joseph Neulen, Katrin Schaudig, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception
|
September 25, 2010
Prescribing preferences and personal experience of female gynaecologists in Germany and Austria regarding use of extended-cycle oral contraceptives
Inka Wiegratz, Katrin Galiläer, Nicole Sänger, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception
|
December 2, 2025
One-year clinical experience on the thromboembolic safety profile of the first prolonged release combined oral contraceptive containing 2 mg dienogest and 0.02 mg ethinyl-oestradiol
Giovanni Grandi, Inka Wiegratz, Alejandro Muñoz, et al.
Contraception
|
October 22, 2008
Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters
Inka Wiegratz, Skadi Stahlberg, Torsten Manthey, et al.
Contraception
|
May 15, 2008
Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use
Nicole Sänger, Skadi Stahlberg, Torsten Manthey, et al.
Fertility and Sterility
|
June 12, 2010
Pregnancy after the calcium ionophore correction of pronuclei position in oocytes after intracytoplasmic sperm injection
Evgenia Isachenko, Vladimir Isachenko, Plamen Todorov, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception
|
February 1, 2023
The drospirenone (DRSP)-only pill: clinical implications in the daily use
Ali Kubba, Kristina Gemzell-Danielsson, Santiago Palacios, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
Fertility and Sterility
|
June 9, 2006
Fertility after discontinuation of treatment with an oral contraceptive containing 30 microg of ethinyl estradiol and 2 mg of dienogest
Inka Wiegratz, Katrin Mittmann, Horst Dietrich, et al.
Reproductive Biology and Endocrinology : RB&E
|
May 28, 2020
Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study
Peter Sydow, Norbert Gmeinwieser, Katrin Pribbernow, et al.
International Journal of Women'S Health
|
January 23, 2015
Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
Inka Wiegratz, Jörg Elliesen, Anna Maria Paoletti, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|
February 18, 2020
Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 μg) and levonorgestrel (150 μg) in a randomized controlled trial
Peyman Hadji, Joseph Neulen, Katrin Schaudig, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception
|
September 25, 2010
Prescribing preferences and personal experience of female gynaecologists in Germany and Austria regarding use of extended-cycle oral contraceptives
Inka Wiegratz, Katrin Galiläer, Nicole Sänger, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception
|
December 2, 2025
One-year clinical experience on the thromboembolic safety profile of the first prolonged release combined oral contraceptive containing 2 mg dienogest and 0.02 mg ethinyl-oestradiol
Giovanni Grandi, Inka Wiegratz, Alejandro Muñoz, et al.
Contraception
|
October 22, 2008
Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters
Inka Wiegratz, Skadi Stahlberg, Torsten Manthey, et al.
Contraception
|
May 15, 2008
Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use
Nicole Sänger, Skadi Stahlberg, Torsten Manthey, et al.
Fertility and Sterility
|
June 12, 2010
Pregnancy after the calcium ionophore correction of pronuclei position in oocytes after intracytoplasmic sperm injection
Evgenia Isachenko, Vladimir Isachenko, Plamen Todorov, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception
|
February 1, 2023
The drospirenone (DRSP)-only pill: clinical implications in the daily use
Ali Kubba, Kristina Gemzell-Danielsson, Santiago Palacios, et al.
Page
of 3